Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M.
Berinstein NL, et al. Among authors: quinton t.
Oncoimmunology. 2015 May 7;4(8):e1026529. doi: 10.1080/2162402X.2015.1026529. eCollection 2015 Aug.
Oncoimmunology. 2015.
PMID: 26405584
Free PMC article.